Biotech billionaire Randal "RJ" Kirk's synthetic biology company Intrexon has announced plans to partner with India's Sun Pharmaceutical on a pipeline of new drugs for ocular diseases, starting with dry age-related macular degeneration.
RJ Kirk has made billions in the biotech business by focusing on the development of new and improved drugs. But now the CEO of synthetic biotech pioneer Intrexon is thinking outside the healthcare box.
The sizzling market for biotech IPOs will end one day, but it won't be today. RJ Kirk's synthetic biology company Intrexon made its debut on Wall Street today and shares quickly zoomed up past the $22 mark, leaving the company with a hefty market value of more than $2 billion and its founder with another fortune.
Germantown, MD-based Intrexon, a synthetic biology outfit led by billionaire Randal Kirk, aims to sell 8.3 million shares at a proposed range of $14 to $16 per share.
Biotech billionaire Randal Kirk will try his luck on the hot IPO market. The CEO, chairman and president of Intrexon has filed papers with the SEC for an initial offering designed to raise up to $125 million, though the final amount often varies in the lead-up to a new listing.
A day after striking the latest in a series of its special "channel" collaborations, Intrexon has reloaded its bank account with a fresh $150 million infusion of cash, with significant added contributions from billionaire founder R.J. Kirk and his venture fund, Third Security.
Biotech billionaire RJ Kirk has hitched another therapeutic developer to his synthetic biology wagon at Intrexon. This time it's Fibrocell Science, an Exton, PA-based developer with a personalized cell therapy for "aesthetic dermatology" on the market.
Biotech startup Intrexon has expanded the synthetic biology shop's ties with drug developer Synthetic Biologics, picking up ownership in the partner as part of a deal focused on generating monoclonal antibodies for infectious diseases.
These days, it's good to have your own money to bank on when you're growing a biotech company. It's also extraordinarily rare. The following 15 venture round qualified as the top investments of the first half, as tracked by Thomson Reuters and the National Venture Capital Association.
Forbes' Matthew Herper went searching for biotech billionaires on the magazine's annual list of the 400 richest Americans but could only scrape together three names: Patrick Soon-Shiong, who sold